New drug mimics benefits of ketamine for depression

A new small-molecule drug produced a rapid antidepressant response similar to that of ketamine when tested in mice, a new Yale-led study published April 16 in the Journal of Clinical Investigation shows. The effects of the drug, called NV-5138, in rodent models mimicked the rapid actions of the anesthetic ketamine, a variation of which, Esketamine, was recently approved by the […]

Read more

FDA approves mavenclad for treating multiple sclerosis

(HealthDay)—Mavenclad (cladribine) tablets were approved to treat adult patients with relapsing-remitting and active secondary progressive multiple sclerosis (MS) who have inadequately responded to or cannot tolerate an alternate drug for MS, the U.S. Food and Drug Administration announced Friday. The approval was based on efficacy data from a clinical trial of 1,326 patients with relapsing forms of MS who had […]

Read more

Group with consumer-friendly vibe pushes drugmakers’ message

Outside groups like the Alliance for Patient Access are raising their voices as they seek to influence deliberations in Washington aimed at lowering prescription drug costs. But not all of these organizations are clear about who they actually represent. Their names can obscure the source of the message and they’re cagey about where their money comes from. The Alliance is […]

Read more

Ketamine-based nasal spray to treat depression

The FDA recently approved a ketamine-based drug to assist with treating depression. The new medication, Spravato, is an intranasal spray that can help those suffering with extreme depression who see little results with psychiatric medications. A Baylor College of Medicine expert discussed the potential impact of the new treatment, which is being marketed as the first fast-acting depression drug. “Ketamine […]

Read more

Many antibiotic courses for common infections not in line with guidelines

Many antibiotic courses prescribed for common infections treated in English primary care (general practices and community services) exceed the recommended guidelines, reveals a study in The BMJ today. Treatment courses were 1.3 million days beyond the durations recommended by guidelines, with most excess days due to treatment for respiratory conditions. Previous studies have found significant over-prescribing of antibiotics in primary […]

Read more

BDNF–VEGF interplay key to rapid antidepressant actions

A study by researchers at Yale University reveals a complex interplay of two different growth factors in the rapid and long-lasting antidepressant effects of ketamine. The study, published in Biological Psychiatry, reports that the antidepressant-like actions of brain-derived neurotrophic factor (BDNF) require the release of vascular endothelial growth factor (VEGF). “Surprisingly, the reciprocal relationship was also observed, indicating that BDNF–VEGF […]

Read more

Antiepileptic drugs linked to increased hospital stays in persons with Alzheimer’s disease

People with Alzheimer’s disease who used antiepileptic drugs had a higher number of accumulated hospital stays than people with Alzheimer’s disease who did not use antiepileptics, according to a new study from the University of Eastern Finland. The results were published in the Journal of American Medical Directors Association. During a two-year follow-up, persons who initiated antiepileptic drugs accumulated approximately […]

Read more
1 2 3